[Shock treatment in the severely injured].
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D000318:Adrenergic beta-Agonists / Q000627:therapeutic use; D000804:Angiotensin II / Q000627:therapeutic use; D001794:Blood Pressure; D001803:Blood Transfusion; D002301:Cardiac Glycosides / Q000627:therapeutic use; D002496:Central Venous Pressure; D004877:Ergoloid Mesylates / Q000627:therapeutic use; D005860:Germany, West; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D007049:Iatrogenic Disease; D007263:Infusions, Parenteral; D007362:Intensive Care Units; D009638:Norepinephrine / Q000627:therapeutic use; D010101:Oxygen Consumption; D011674:Pulse; D012771:Shock, Hemorrhagic / Q000175:diagnosis / Q000628:therapy*; D012772:Shock, Septic / Q000209:etiology / Q000628:therapy; D012774:Shock, Traumatic / Q000628:therapy*; D013300:Streptokinase / Q000627:therapeutic use
D000317:Adrenergic alpha-Antagonists; D000318:Adrenergic beta-Agonists; D002301:Cardiac Glycosides; D000804:Angiotensin II; D004877:Ergoloid Mesylates; D006493:Heparin; D013300:Streptokinase; D009638:Norepinephrine
Die Schockbehandlung des Schwerverletzten.